

Grünenthal's response to Covid-19, the new coronavirus

Grünenthal considers the outbreak and spread of Covid-19 (known as new coronavirus) to be a serious situation and fully recognises its responsibilities related to safeguarding the well-being and safety of our employees, ensuring an uninterrupted supply of our medicines for patients, and supporting communities with curbing the Covid-19 outbreak.

We have installed global and local crisis teams to ensure a well-coordinated and targeted response to the Covid-19 outbreak for our company. These teams are constantly monitoring the situation and taking immediate and appropriate decisions based on the company's crisis governance framework, advice from the World Health Organization, and national and local government bodies.

Grünenthal is driving awareness among employees and emphasising the need to prevent the spread of the virus by following hygiene rules. We have implemented a series of measures in light of the Covid-19 outbreak. All measures are reviewed by the crisis teams on a daily basis and adapted to take new developments into account. The information below represents the status on 24th April 2020.

Business travel restrictions

Grünenthal has implemented global business travel restrictions stating that our employees must not travel for business using public transportation including planes, trains and buses. Business travel by car should only take place when the trip is business-critical and cannot be postponed. Our travel restrictions also apply to business partners who are visiting one of our sites.

Extended remote working policy

Grünenthal has advised all of its office- and field-based employees worldwide to work remotely.

In addition, employees who belong to high-risk groups – including people aged over 60 and those with underlying medical conditions such as cardiovascular disease, diabetes or chronic respiratory disease – have been specifically advised to stay at home.

Grünenthal employees who have had contact with an infected person or have visited a high-risk area must not come to work. Instead, they are asked to consult a doctor immediately and work remotely for at least 14 days.

Current status at our production sites

To maintain the production and supply of medicines for patients, Grünenthal is closely monitoring the situation at its production sites and throughout its supply chain.

Grünenthal's production site in Italy – as well as all other sites – is being managed carefully and we are constantly assessing the situation as it develops. Employees have been advised to adhere to very strict hygiene rules. Currently, all sites are operating.

At our headquarters and all production sites, the number of external visitors is being kept to a minimum. For example, all appointments with external parties are being postponed unless they are



business-critical. Before entering Grünenthal's production sites, the body temperature of all visitors and all staff from external companies or third parties is measured.

Current status within our supply chain

We are currently not experiencing any significant supply shortages. However, Grünenthal purchases raw materials and finished products directly and indirectly globally, including major pharmaceutical supply markets such as China and India. In this context, we are in close exchange with our brokers and suppliers, and are constantly monitoring the situation. In general, Grünenthal follows a strict inventory and safety stock policy that enables us to mitigate short-term supply shortages and ensure that we can supply our products to patients. If our Business Continuity team detects any severe supply shortages that might potentially disrupt the supply of our products, we will inform our affected partners as well as health authorities and other official bodies as soon as possible.

M-N/A-UK-04-20-0014 April 2020